Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 50, 2013, Pages 20200-20205

  Jones, Joanne L ^a   Thompson, Sara A J ^a   Loh, Priscilla ^b   Davies, Jessica L ^a   Tuohy, Orla C ^a   Curry, Allison J ^a   Azzopardi, Laura ^a   Hill Cawthorne, Grant ^a,c   Fahey, Michael T ^b,d   Compston, Alastair ^a   Coles, Alasdair J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CSIRO   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Immunotherapy; Reconstitution; T lymphocytes

Indexed keywords

ALEMTUZUMAB; AUTOANTIBODY; BETA1A INTERFERON; CD28 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; KI 67 ANTIGEN; OLIGOCLONAL BAND;

ARTICLE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL PROLIFERATION; CLONAL VARIATION; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; FEMALE; GOODPASTURE SYNDROME; GRAVES DISEASE; HOMEOSTASIS; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIDE EFFECT; T LYMPHOCYTE; THYROID DISEASE;

EID: 84890285333     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1313654110     Document Type: Article

References (48)

1. Cohen JA, et al. (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 380(9856):1819-1828.
2. Coles AJ, et al. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786-1801.
3. Coles AJ, et al. (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 380(9856):1829-1839.
4. Hill-Cawthorne GA, et al. (2012) Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 83(3):298-304.
5. Khoruts A, Fraser JM (2005) A causal link between lymphopenia and autoimmunity. Immunol Lett 98(1):23-31.
6. McHugh RS, Shevach EM (2002) Cutting edge: Depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 168(12):5979-5983.
7. Kassiotis G, Zamoyska R, Stockinger B (2003) Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells. J Exp Med 197(8):1007-1016.
8. Kieper WC, Burghardt JT, Surh CD (2004) A role for TCR af finity in regulating naive T cell homeostasis. J Immunol 172(1):40-44.
9. Cho JH, Kim HO, Surh CD, Sprent J (2010) T cell receptor-dependent regulation of lipid rafts controls naive CD8+ T cell homeostasis. Immunity 32(2):214-226.
10. Goldrath AW, Bogatzki LY, Bevan MJ (2000) Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 192(4):557-564.
11. Murali-Krishna K, Ahmed R (2000) Cutting edge: Naive T cells masquerading as memory cells. J Immunol 165(4):1733-1737.
12. King C, Ilic A, Koelsch K, Sarvetnick N (2004) Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117(2):265-277.
13. Le Saout C, Mennechet S, Taylor N, Hernandez J (2008) Memory-like CD8+ and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions. Proc Natl Acad Sci USA 105(49):19414-19419.
14. Brenchley JM, et al. (2003) Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101(7):2711-2720.
15. Wherry EJ (2011) T cell exhaustion. Nat Immunol 12(6):492-499.
16. Cox AL, et al. (2005) Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 35(11):3332-3342.
17. Bloom DD, et al. (2008) CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 8(4):793-802.
18. Thornton AM, et al. (2010) Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 184(7):3433-3441.
19. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW (2011) Helios expression is a marker of T cell activation and proliferation. PLoS One 6(8):e24226.
20. Borsellino G, et al. (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 110(4):1225-1232.
21. Kimmig S, et al. (2002) Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med 195(6):789-794.
22. Dulude G, et al. (2008) The magnitude of thymic output is genetically determined through controlled intrathymic precursor T cell proliferation. J Immunol 181(11):7818-7824.
23. Hug A, et al. (2003) Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J Immunol 171(1):432-437.
24. Bomberger C, et al. (1998) Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 91(7):2588-2600.
25. Jones JL, et al. (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119(7):2052-2061.
26. Kilpatrick RD, et al. (2008) Homeostasis of the naive CD4+ T cell compartment during aging. J Immunol 180(3):1499-1507.
27. den Braber I, et al. (2012) Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity 36(2):288-297.
28. Stockinger H, et al. (1992) Phenotype of human T cells expressing CD31, a molecule of the immunoglobulin supergene family. Immunology 75(1):53-58.
29. Azevedo RI, et al. (2009) IL-7 sustains CD31 expression in human naive CD4+ T cells and preferentially expands the CD31+ subset in a PI3K-dependent manner. Blood 113(13):2999-3007.
30. Hazenberg MD, et al. (2000) Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 6(9):1036-1042.
31. Hu Y, et al. (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128(2):260-270.
32. Moreau T, et al. (1996) Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119(Pt 1):225-237.
33. Guimond M, et al. (2009) Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol 10(2):149-157.
34. Fortner KA, Budd RC (2005) The death receptor Fas (CD95/APO-1) mediates the deletion of T lymphocytes undergoing homeostatic proliferation. J Immunol 175(7):4374-4382.
35. Workman CJ, Vignali DA (2005) Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 174(2):688-695.
36. Strioga M, Pasukoniene V, Characiejus D (2011) CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology 134(1):17-32.
37. Sun Z, et al. (2008) Association of Graves' disease and prevalence of circulating IFN-gamma-producing CD28(-) T cells. J Clin Immunol 28(5):464-472.
38. Dai H, et al. (2010) Cutting edge: Programmed death-1 defines CD8+CD122+ T cells as regulatory versus memory T cells. J Immunol 185(2):803-807.
39. Deaglio S, et al. (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204(6):1257-1265.
40. Moxham VF, et al. (2008) Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated allograft rejection. J Immunol 180(6):3910-3918.
41. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA (2000) Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 123(Pt 6):1102-1111.
42. Heinzlef O, et al. (2000) Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand 101(1):36-40.
43. Kappos L, et al. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805):1779-1787.
44. Habek M, et al. (2012) Thyroid autoimmunity in comparison of alemtuzumab and Rebif efficacy in multiple sclerosis studies I and II. J Neurol 259(Suppl 1):S1-S236.
45. Kirk AD, et al. (2003) Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76(1):120-129.
46. Knechtle SJ, et al. (2003) Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 3(6):722-730.
47. Wada T, Schurman SH, Garabedian EK, Yachie A, Candotti F (2005) Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome. Blood 106(12):3895-3897.
48. Robins HS, et al. (2009) Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114(19):4099-4107.